TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19947273
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (oral Chlorpheniramine and topical zinc oxide ointment or Youzhuoer ointment)
Study: 16924568
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (NB) 4 mg/day
Study: 16924568
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid (SC) 1 mg/kg/day methylprednisolone
Study: 9075036
Drug: High thoracic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High thoracic epidural anesthesia (HTE) with 2% lidocaine 5 ml
Study: 17566093
Drug: Flutamide 125
Normalized name: flutamide 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 125 mg
Study: 17566093
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg
Study: 17566093
Drug: Flutamide 375
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 375 mg
Study: 8503338
Drug: Flutamide 750
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 750 mg
Study: 8503338
Drug: Flutamide 1125
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 1125 mg
Study: 8503338
Drug: Flutamide 1500
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 1500 mg
Study: 8503338
Drug: Flutamide 1500
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 1500 mg/day
Study: 8503338
Drug: Flutamide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (various doses)
Study: 3100110
Drug: 4 IU
Normalized name: Cholecalciferol/Vitamin E 14000 IU-34 IU Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU hGH, subcutaneously, 12-hourly for 72 hours before GHRH test
Study: 3100110
Drug: 4 IU
Normalized name: Cholecalciferol/Vitamin E 14000 IU-34 IU Oral Wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU hGH, single subcutaneous dose, 12 hours before GHRH test
Study: 3100110
Drug: Placebo, subcutaneously,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, subcutaneously, 12-hourly for 72 hours before GHRH test
Study: 27637735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received treatment after crossover)
Study: 29408304
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of automated plus live prompts
Study: 16483391
Drug: Low-dose, high-concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, high-concentration localized botulinum toxin A (BTX-A) injections (total dose 82-220 units, mean 139 [SD 37.48]; dilution 100 units/0.5ml)
Study: 16483391
Drug: Low-dose, high-concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, high-concentration localized botulinum toxin A (BTX-A) injections
Study: 4027872
Drug: PALA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA alone (800 to 1000 mg/m2 per day for 5 days every 2 weeks)
Study: 4027872
Drug: PALA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA + 5-FU (PALA: 400 mg/m2 per day for 5 days, 5-FU: 300 mg/m2 per day for 5 days every 28 days)
Study: 4027872
Drug: 5-FU alone
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU alone (300 to 400 mg/m2 per day for 5 days every 21 days)
Study: 30513988
Drug: Juçara supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juçara supplementation (5 g juçara freeze-dried pulp)
Study: 27263403
Drug: Maternal Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal Hb concentration ≤109 g/L during 24-28 weeks of gestation
Study: 27263403
Drug: Maternal Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal Hb concentration 120-129 g/L during 24-28 weeks of gestation
Study: 27263403
Drug: Maternal Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal Hb concentration ≥130 g/L during 24-28 weeks of gestation
Study: 22723003
Drug: AC+CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC+CC genotype
Study: 14560861
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg/kg
Study: 10232312
Drug: co‐trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole (800 mg/160 mg)
Study: 1987739
Drug: Intracavitary brachytherapy
Normalized name: carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavitary brachytherapy boost (10-15 Gy) following external beam radiation therapy (60-64 Gy).
Study: 1987739
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy alone (65-70 Gy).
Study: 6132178
Drug: Meptazinol, 300-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol, 300-500 mg intravenously
Study: 6132178
Drug: Naloxone, 30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone, 30-40 mg intravenously
Study: 29353631
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 5% aqueous solution (double dose)
Study: 22938716
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 μg daily
Study: 22938716
Drug: Nedocromil 16
Normalized name: NEDOCROMIL
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil 16 mg daily
Study: 22938716
Drug: Inhaled glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoids (higher doses in first 2 years)
Study: 12784695
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine (EBM) practices in stroke management
Study: 9849415
Drug: Non-oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-oral contraceptive users
Study: 2152803
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg oral solution
Study: 2152803
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg tablet
Study: 7855966
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tablet
Study: 2152803
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg intravenous infusion
Study: 2152803
Drug: All oral
Normalized name: Exall Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: All oral doses
Study: 380912
Drug: Levamisole (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.0 to 2.5 mg per kg body weight, single dose on 1 day per week for 4 months)
Study: 27977473
Drug: Bremelanotide 1.75
Normalized name: BREMELANOTIDE 1.75MG/0.3ML AUTOINJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bremelanotide 1.75 mg
Study: 31658134
Drug: Nicorandil therapy
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil therapy (nicorandil 10 mg three times daily plus hydration)
Study: 31658134
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (hydration only)
Study: 31658134
Drug: Nicorandil therapy
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil therapy
Study: 19407444
Drug: aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (100 mg/day)
Study: 28062625
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin I (hs-TnI) >26 ng/L
Study: 28062625
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin I (hs-TnI) <1.9 ng/L
Study: 28062625
Drug: Vorapaxar in
Normalized name: Product containing vorapaxar in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar in patients with hs-TnI >26 ng/L
Study: 28062625
Drug: Vorapaxar in
Normalized name: Product containing vorapaxar in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar in patients with hs-TnI <1.9 ng/L
Study: 26440235
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a rate of 120 mcg/kg/min starting immediately after CPB and maintained throughout surgery and for 6 hours in ICU
Study: 26440235
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at a dose of 30-50 mcg/kg/min starting at chest closure and continued for 6 hours in ICU
Study: 15906019
Drug: Tramadol-HCl 100
Normalized name: Tramadol Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-HCl 100 mg
Study: 15906019
Drug: Tramadol-HCl 150
Normalized name: tramadol hydrochloride 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-HCl 150 mg
Study: 15906019
Drug: Tramadol-HCl 50
Normalized name: tramadol hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol-HCl 50 mg
Study: 12270852
Drug: Sitaxsentan (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan (selective ET(A) receptor antagonist) infused at increasing rates (0.3125 to 10 mg/min) in patients with HF
Study: 12270852
Drug: Sitaxsentan (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan (selective ET(A) receptor antagonist) infused in control subjects
Study: 9638665
Drug: Various chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various chemotherapy protocols (SIOP 1, SIOP 2, HDMTX/VCR, HIT protocol 89/91, Carbo-PEI)
Study: 9638665
Drug: HIT protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIT protocol 89/91 as first-line treatment
Study: 9638665
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (surgery and radiotherapy alone)
Study: 27447160
Drug: Test implant
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implant system
Study: 27447160
Drug: Predicate implant
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Predicate implant system
Study: 25197812
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of normal saline (22 mL/kg body weight) after sleep onset with compression stockings to prevent fluid accumulation in the legs.
Study: 25197812
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion to keep the vein open (control arm).
Study: 20961386
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel (CHX-Gel)
Study: 20961386
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine dentifrice-gel (CHX-DFG)
Study: 20961386
Drug: 1% CHX-Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% CHX-Gel and 0.2% CHX-MW
Study: 18381138
Drug: Statin use,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use, beta-blockers, antiplatelet drugs
Study: 9140517
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with standardized extracts of Dermatophagoides pteronyssinus and D. farinae
Study: 2884454
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 33B3.1 daily by intravenous infusion for 14 days (group A)
Study: 2884454
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 33B3.1 daily by intravenous infusion for 14 days (group B)
Study: 31707498
Drug: Clobetasol lotion
Normalized name: clobetasol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol lotion
Study: 29616028
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral (DAA) drug therapies
Study: 29616028
Drug: HCV clearance
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV clearance by DAA drug therapy
Study: 25285994
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement containing Phyllanthus emblica (100 mg), vitamin E (10 mg), and carotenoids (4.7 mg) three times/day for 6 months
Study: 18457936
Drug: Amoxicillin three-times-daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin three-times-daily (TD)
Study: 18457936
Drug: Roxithromycin once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin once-daily (OD)
Study: 18457936
Drug: Placebo once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once-daily (OD)
Study: 18457936
Drug: Placebo three-times-daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo three-times-daily (TD)
Study: 29633652
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy Group (MTG) - 10 individual sessions of music therapy (30-40 minutes each) with a trained music therapist.
Study: 29633652
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - standard care without music therapy.
Study: 25285887
Drug: Tat1-86 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tat1-86 (25 μg)
Study: 19694216
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/d) for 3 months
Study: 16796606
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (steady-state concentration of 100 mU L(-1))
Study: 9227168
Drug: Corticosteroid (triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (triamcinolone acetonide, TA) injection
Study: 9227168
Drug: Yttrium-90 plus
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90 plus corticosteroid (TA+Y) injection
Study: 26135351
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg crystalline vitamin B‐12 daily for 12 months
Study: 20032798
Drug: Ospemifene 30
Normalized name: Ospemifene
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ospemifene 30 mg/day
Study: 20962160
Drug: Iron-fortified biscuits
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified biscuits (20 mg Fe/d, 4 times/week)
Study: 18785059
Drug: CHO‐E solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO‐E solution (6% carbohydrate, 50 mg Na/500 ml)
Study: 16598386
Drug: Topical metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical metronidazole (Noritate 1% Cream, MetroCream 0.75% Cream, MetroLotion 0.75% Lotion, Metrogel 0.75% and 1% Topical Gel)
Study: 10671842
Drug: Conventional syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional syringe and 25 G needle
Study: 9323734
Drug: Acuvue lenses
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acuvue lenses with UV blocker
Study: 9323734
Drug: Conventional Acuvue
Normalized name: Acuvue Theravision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Acuvue lenses without UV blocker
Study: 3094139
Drug: Imipenem/cilastatin 500/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500/500 mg q6h (77 patients, 56 evaluable for efficacy)
Study: 3094139
Drug: Gentamicin 1.5
Normalized name: HYDROCORTISONE ACEPONATE 1.11 mg in 1 mL / MICONAZOLE NITRATE 17.4 mg in 1 mL / GENTAMICIN 1.5 mg in 1 mL AURICULAR (OTIC) SUSPENSION [EASOTIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.5 mg/kg plus clindamycin 600 mg q6h (86 patients, 62 evaluable for efficacy)
Study: 30508538
Drug: Sublingual high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual high-dose liquid birch pollen extract (40,000 AUN/mL)
Study: 18839644
Drug: Oral thiocolchicoside
Normalized name: thiocolchicoside
DrugBank: Thiocolchicoside (DB11582)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thiocolchicoside (TC) for one week
Study: 18839644
Drug: Adrenergic alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenergic alpha 2 agonist tizanidine (TZ) for one week
Study: 15295717
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg
Study: 11294048
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg and Lisinopril 20 mg (combination treatment)
Study: 9272261
Drug: Fluoxetine 3
Normalized name: fluoxetine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 3 x 20 mg/day
Study: 25920634
Drug: Leukocyte-poor (type-4B)
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-poor (type-4B) PRP injection
Study: 10211492
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine injection
Study: 19684043
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Corifollitropin alfa (150 microg single injection)
Study: 19684043
Drug: Recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant FSH (200 IU daily injections)
Study: 11878407
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg/saquinavir 400 mg twice daily plus one NRTI
Study: 11878407
Drug: Indinavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir 800 mg once every 8 hours plus two NRTIs
Study: 9894650
Drug: Transvenous lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvenous lead system with additional subcutaneous lead
Study: 8000154
Drug: Increased trace
Normalized name: Trace metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased trace element intake (4.5 mg Cu, 190 micrograms Se, and 40 mg Zn/day)
Study: 31608373
Drug: Program 4
Normalized name: Program 410 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Program 4 (community-based HIV care program + nutritional education + food supplement)
Study: 31608373
Drug: Programs 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programs 3 (community-based HIV care program + food supplement) and 4 (all elements of Programs 1-3)
Study: 21564071
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg weekly for 8 weeks, then 15 mg weekly for ER, 20 mg weekly for 4 weeks for LR, or 25 mg weekly for LN if not achieving PASI 50.
Study: 21564071
Drug: Methotrexate 20
Normalized name: METHOTREXATE 20MG/0.8ML SOLN INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 20 mg weekly for late responders (LR) after initial 15 mg weekly.
Study: 21564071
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg weekly for late nonresponders (LN) if not achieving PASI 50 at week 12.
Study: 14514222
Drug: 2.8 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 mm neck implants
Study: 14514222
Drug: Neck implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck implants
Study: 8403788
Drug: Hormone infusion
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone infusion study (glucagon, adrenaline, noradrenaline, cortisol, growth hormone)
Study: 8403788
Drug: Hypoglycaemia study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypoglycaemia study (plasma glucose lowered to 2.8 mmol/l)
Study: 30877742
Drug: M-mZnO (20.90
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-mZnO (20.90 m2/g)
Study: 30877742
Drug: Micronized ZnO
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Micronized ZnO groups (S-mZnO, M-mZnO, L-mZnO)
Study: 26414653
Drug: Etoricoxib (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (90 mg)
Study: 15352967
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg)
Study: 26414653
Drug: Etoricoxib (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (90 mg) and Diclofenac (75 mg)
Study: 7805083
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for DVT based on anatomic extent of thrombus
Study: 31726034
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate 1% (PA 1%) self-administered daily (tapered schedule, days 0‐28)
Study: 31726034
Drug: Topical prednisolone
Normalized name: prednisolone Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical prednisolone acetate 1% (PA 1%)
Study: 22776627
Drug: Helmet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helmet therapy
Study: 22859320
Drug: Original salbutamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original salbutamol (5 mg, 20 drops in nebulizing solution)
Study: 22859320
Drug: Similar salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Similar salbutamol (5 mg, 20 drops in nebulizing solution)